United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
United Therapeutics (UTHR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$318.09 | $400.00 | $240.00 | -5.54% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for United Therapeutics comes to $318.09. The forecasts range from a low of $240.00 to a high of $400.00. The average price target represents a decline of 5.54% from the last closing price of $336.74.
Analyst Price Targets (11)
Broker Rating
United Therapeutics currently has an average brokerage recommendation (ABR) of 1.69 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy, representing 69.23% of all recommendations. A month ago, Strong Buy represented 76.92%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 10 | 11 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.69 | 1.69 | 1.54 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
7/8/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
6/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/12/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Strong Buy |
5/3/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
5/2/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/15/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
2/5/2024 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
11/2/2023 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
11/1/2023 | BTIG | Julian Harrison | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.69 |
ABR (Last week) | 1.69 |
# of Recs in ABR | 13 |
Average Target Price | $318.09 |
LT Growth Rate | 9.20% |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | 6.24 |